Chimerix’s ONC201 Study: A New Hope for Glioma Patients?

Chimerix ((CMRX)) announced an update on their ongoing clinical study.

The ACTION Study, officially titled ‘ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy,’ is a Phase 3 clinical trial conducted by Chimerix. The study aims to determine if ONC201, administered after standard radiotherapy, can improve overall and progression-free survival in patients with this specific type of brain tumor. This research is significant as it targets a rare and aggressive cancer, potentially offering new hope for affected patients.

The study tests the drug Dordaviprone (ONC201), which is administered in two experimental groups: one receiving the drug twice weekly and another once weekly alongside a placebo. The purpose of the drug is to extend survival rates in patients post-radiotherapy.

This clinical trial is designed as a randomized, double-blind, placebo-controlled study with a parallel intervention model. It involves triple masking, meaning the participant, care provider, and investigator are unaware of the group assignments, ensuring unbiased results. The primary aim is to evaluate the treatment’s effectiveness.

The study began on January 23, 2023, and is currently recruiting participants. The last update was submitted on July 7, 2025. These dates are crucial as they indicate the study’s progress and timelines for potential results.

Chimerix’s stock performance could be positively influenced by this study, as successful results may enhance investor confidence and market position. The study’s focus on a rare cancer type also positions Chimerix uniquely within the pharmaceutical industry, potentially setting it apart from competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.